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At a glance 
 
Scientific Knowledge on the Subject 
Non-adherence with inhaled corticosteroids (ICS) in severe asthma is common and 
consistently associated with poor clinical outcomes. Assessment of adherence to ICS is 
challenging with physician estimates and patient self-reports overestimating adherence 
when compared to objective measures. The development and validation of protocol-driven 
adherence assessments would minimise the risk of committing a patient to long-term 
biological treatment when their disease is readily controllable with ICS.  
 
What This Study Adds to the Field 
The FeNO suppression test, delivered using remote monitoring technology, is 
straightforward for both the patient and the clinician, and demonstrates the value of 
alignment of an ICS responsive biomarker (FeNO) with an inhaler monitoring technology. 
Profiling the FeNO response to ICS in subjects with difficult-to-control severe asthma is a 
helpful part of clinical phenotyping, and can identify those who are likely to respond well 
to high dose ICS/LABA therapy when taken regularly, and those, who despite good 
adherence with inhaled treatment, are likely to require additional interventions.  
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Abstract 
Rationale 
Poor adherence is common in difficult-to-control asthma. Distinguishing patients with difficult-to-
control asthma who respond to inhaled corticosteroids (ICS) from refractory asthma is an important 
clinical challenge. 
  
Objectives 
Suppression of fractional exhaled nitric oxide (FeNO) with directly observed ICS therapy over 7 
days can identify non-adherence to ICS treatment in difficult-to-control asthma. We examined the 
feasibility and utility of FeNO suppression testing in routine clinical care within UK severe asthma 
centres using remote monitoring technologies. 
 
Methods 
A web-based interface with integrated remote monitoring technology was developed to deliver 
FeNO suppression testing. We examined the utility of FeNO suppression testing to demonstrate ICS 
responsiveness and clinical benefit on electronically-monitored treatment with standard high dose 
ICS and long-acting β2-agonist (LABA) treatment. 
 
Measurements and Main Results 
Clinical response was assessed using the Asthma Control Questionnaire (ACQ-5), spirometry and 
biomarker measurements (FeNO and peripheral blood eosinophil count). Of 250 subjects, 201 
completed the test with 130 positive suppression tests. Compared to a negative suppression test, a 
positive test identified a FeNO-low population when adherent with ICS/LABA (median 26ppb 
[IQR 16–36] v 43ppb [IQR 38–73]) with significantly greater FEV1%  (mean 88.2±16.4 v 
74.1±20.9], p<0.01). ACQ-5 improved significantly in both groups (positive test, mean 
difference -1.2, 95% CI -0.9, -1.5, negative test, mean difference -0.9, 95% CI -0.4, -1.3). 
2 
 
Conclusions  
Remote FeNO suppression testing is an effective means of identifying non-adherence to ICS in 
subjects with difficult-to-control asthma and the substantial population of subjects who derive 
important clinical benefits from optimised ICS/LABA treatment. 
 
Total word count of abstract: 250 
Indexing terms: asthma, inhaler, monitoring, technology 
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Introduction 
Non-adherence with inhaled corticosteroids (ICS) in poorly controlled severe asthma is common 
and associated with worse clinical outcomes1,2,3. Assessment of adherence to inhaled treatments is 
challenging: physician estimate and patient self-report consistently overestimate adherence when 
compared to objective measures, and other surrogate measures such as prescription collection 
records have limitations4,5. The advent of novel biologic therapies targeting type-2 cytokines in 
severe asthma makes identification of sub-optimal adherence to ICS important so that the issue can 
be addressed prior to committing a patient to a long-term parenteral therapy. Inhaler monitoring 
technologies remain the gold standard in clinical trials but clinical services have been slow to 
embrace these as part of routine care. They are perceived as potentially expensive and cumbersome, 
and there may be concern from healthcare professionals to challenge non-adherent behaviour or 
engage subjects to provide long term meaningful change in adherence behaviour. 
 
Suppression of fractional exhaled nitric oxide (FeNO) is an easily measured predictor of ICS 
response 6,7,8. Directly observed ICS treatment over seven days in subjects with a high FeNO (FeNO 
≥45ppb) can identify subjects with difficult-to-control severe asthma who are responsive to ICS and 
non-adherent with their maintenance ICS treatment (FeNO suppression test [FeNOSuppT] - further 
detail see online supplement)9. A value of ≥45ppb was chosen because in subjects with severe 
asthma, it is associated with frequent exacerbations10 and it identifies subjects who respond to 
treatment with ICS6,11. Thus, in poorly controlled severe asthma and FeNO ≥45ppb, the key clinical 
issue is whether subjects are taking their ICS treatment effectively or whether they need treatment 
escalation. 
 
The aim of this work was to assess the utility of home-based delivery of the FeNOsuppT using a 
remote monitoring technology that assess both time of use and inhaler technique thereby enabling 
“directly observed therapy” to identify subjects who would achieve good asthma control with better 
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inhaler technique or adherence to inhaled treatment. Some of the results of this study has been 
previously reported in the form of an abstract12. 
 
Methods 
This was a prospective evaluation of the FeNOsuppT in subjects attending UK severe asthma 
centres involved in the UK Refractory Asthma Stratification Programme (RASP-UK)13 (see online 
supplement). The Health Research Authority Research UK Ethics Committee and the Research 
Leads of participating centres approved the study as a clinical service evaluation.  
 
The inhaler monitoring technology used was the INCA™ device, designed to work with the 
Diskus™ inhaler (Figure e1, online supplement)14. This acoustic monitoring technology provides a 
time stamped sound file which can be analysed using an automated validated algorithm providing 
information on the timing and the technique of inhaler usage (figure e2, online supplement)14. 
FeNO was measured using the Niox VERO™ and all clinical services were provided with the 
inhaler monitoring and FeNO technology with appropriate training for clinical staff in its use. 
 
Subjects considered for FeNOsuppT were referrals to a severe asthma clinic with poor asthma 
control despite prescription of high dose ICS in combination with long-acting β2-agonist 
(ICS/LABA) and an elevated FeNO (defined as FeNO≥45ppb – high FeNO group). Subjects were 
asked to measure their FeNO daily and to take high dose ICS for seven days (1000 µg fluticasone 
per day) via the Diskus™ with an INCA™ device, in addition to their usual ICA/LABA. Printed 
instruction sheets for the inhaler and the Niox VERO were given to each patient.  
 
On return to the clinic, results from both the INCA™ device and the Niox VERO™ were uploaded 
to a server using the Vitalograph IC Data Compression Utility application and analysed using the 
embedded sound analysis algorithm (Figure e3, online supplement). A FeNOsuppT test was defined 
5 
 
as previously9 but in effect, a 42% fall in FENO between the Day 0/Day 1 and the Day 4/Day 5 
mean values equates to a positive suppression test. If a patient could use the Diskus device 
efficiently based on the FeNOSuppT monitoring profile, they were offered the opportunity to 
replace their current ICS/LABA with salmeterol 50µg/fluticasone 500µg Diskus one inhalation 
twice per day with an INCA™ device, and were informed that inhaler use was being monitored for 
a one month period (Figure e4, online supplement),  
 
After one month of monitoring, the relationship between the FeNOsuppT and biomarker (FeNO and 
peripheral blood eosinophil count) and clinical outcomes (Asthma Control Questionnaire (ACQ-5) 
and spirometry) in subjects with good adherence was examined. Good adherence was defined as 
≥70% adherence using the INCA™  device as previously in a clinical trial setting, mean adherence 
was 73% using biofeedback and thus likely to be best achievable in a real-world setting14. 
 
In parallel, a sub-group of subjects with poor asthma control despite high dose ICS/LABA 
treatment and FeNO<45ppb at one clinical centre (Belfast) (low FeNO group), were offered 
INCA™ monitoring. They were instructed in the use of Accuhaler device, and if they could use it 
efficiently (based on use of a training device at clinic), they were provided with salmeterol 
(50µg/fluticasone 500µg Diskus one inhalation twice per day) with an INCA™ device, to be taken 
in the morning and in the evening for one month. 
 
Statistical analysis 
Data were anonymised and collected in a systematic manner to allow reporting of the utility of the 
testing in routine clinical care. Normally distributed variables data were presented using the mean  
standard deviation. Mean differences were calculated with 95% confidence intervals, and 
independent and paired t-tests were used to formally compare between groups. Non-normally 
distributed variables were presented using the median and the interquartile range. Median 
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differences were calculated with bootstrapped 95% confidence intervals, and the Mann-Whitney U 
test or Wilcoxon signed-rank test were used to formally compare between groups. Chi-squared tests 
were used to test for differences across groups for categorical variables. Correlation analyses were 
conducted using the Spearman’s rank test. All statistical analyses were performed using STATA 
version 14. 
 
Results 
Patient disposition and demographic details for high and low FeNO groups are shown in Figure 1 
and Table e1 in the online supplement. 
 
FeNO Suppression test 
Of 250 subjects with FeNO≥45ppb who performed a FeNOsuppT, 49 of 250 (20%) subjects were 
unable to perform the test – 16 (6%) did not measure their FeNO daily and 33 (13%) had critical 
inhalation errors or missed multiple doses (<70% of ICS during FeNOSuppT) of the additional 
inhaler over a single week. This was despite awareness that inhaler usage was being monitored and 
despite detailed verbal and written instructions, and a proven initial ability to measure their FeNO 
and use the Diskus efficiently in the clinic. 
 
Of the remaining 201 subjects who successfully performed a FeNOsuppT, 130 (65%) were positive 
and 71 had negative tests (35%) (figure 2, FeNO suppression curves as % of baseline are shown in 
figure e5 in the online supplement). Subjects with a positive suppression test had similar levels of 
FeNO at the start of the test, but were younger (p<0·001), more likely to be female (p=0.007), had 
higher rates of atopic eczema (p<0·001), higher IgE levels (p=0.012) and were less likely to be on 
maintenance prednisolone (p=0·025) (Table 1). 
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There was no difference in baseline FeNO in subjects with a positive suppression test on 
maintenance prednisolone (median 84ppb, IQR 65, 111) compared to subjects not taking 
prednisolone (median 92ppb, IQR 63-127) whereas blood eosinophils were significantly lower in 
subjects on prednisolone (median 0.40 x109/L, IQR 0.19, 0.61 versus 0.56 x109/L, IQR 0.30-0.84, 
p<0.01). In subjects prescribed maintenance prednisolone, 61 (58%) had a positive suppression test 
and 45 (42%) had a negative test and there was an identical pattern of FeNO suppression in subjects 
taking prednisolone compared with subjects not taking prednisolone with no differences in baseline, 
Day 4 or Day 7 FeNO levels (figure e6 online supplement). This was also was the case in those 
subjects on maintenance prednisolone with contemporaneous positive prednisolone / cortisol levels 
on Day 0 (n=59, data not shown). 
 
Blood eosinophil counts (figure 3a and 3b) fell significantly from Day 0 to Day 7 in those subjects 
who had a positive FeNOsuppT [median difference = -0.14 (95% CI -0.03, -0.23), p<0.001] but not 
in subjects with a negative suppression test [median difference = 0.02 (95% CI -0.12, 0.14), 
p=0.684]. This difference was more apparent for subjects not on maintenance prednisolone; after a 
positive FeNOsuppT from Day 0 to Day 7 [median difference = - 0.21 (95% CI -0.27, -0.11), 
p<0.001] but not in those subjects with a negative suppression test [median difference = 0.06 (95% 
CI -0.25, 0.45), p=0.842] (figure 3c and 3d). 
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Figure 1. Flow diagram showing the disposition of subjects assessed by severe asthma services 
with difficult-to-control asthma (n=290). Subjects with FeNO≥45ppb (multicentre high FeNO 
group, n=250) had FeNO suppression testing and if they liked the Diskus and could use the device 
proficiently proceeded to one month monitored treatment with high dose ICS/LABA (salmeterol 
50µg/fluticasone 500µg Diskus one inhalation twice per day). Subjects with FeNO<45ppb (single 
centre low FeNO group, n=40) had identical one month monitored treatment. 
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Table 1. Baseline patient characteristics of the 201 subjects with FeNO≥45ppb who successfully 
performed a FeNO suppression test. Data are shown as median (IQR), mean (SD) or n (%) as 
appropriate. 
 
 
a = atopy defined with immunology test; skin prick or RAST positive to inhaled perennial allergen 
(cat, dog, house dust mite, mixed grasses) b = baseline dose of inhaled steroid as prescribed are 
equivalent dose of beclomethasone dipropionate (BDP)  
 Positive FeNO 
suppression test 
(n=130) 
Negative FeNO 
suppression test 
(n=71) 
P value 
Female, n (%) 86 (66.2%) 33 (46.5%) 0.007 
Age, (years) 38.8 (15.4) 49.8 (13.8) <0.001 
Smoking, n (%)   0.539 
Never smoked 100 (76.9%) 54 (76.1%)  
Ex-smoker 26 (20.0%) 16 (22.5%)  
Current smoker   2 (1.5%) 0 (0.0%)  
Data not available (n=3)    
Atopic, n (%)a 84 (64.6%) 39 (54.9%) 0.102 
Data not available (n=4)    
ACQ-5  3.0 (1.4) 2.5 (1.4) 0.028 
FeNO (ppb)  85 (64,125) 78 (57,118) 0.251 
Eosinophils ( cellsx109/L) 0.50 (0.22,0.79) 0.39 (0.25,0.65) 0.428 
Inhaled steroid (BDP equivalent µg)b 1727 (757) 1670 (643) 0.598 
On maintenance prednisolone, n (%) 61 (46.9%) 45 (63.4%) 0.025 
Prednisolone dose (mg) 12.7 (7.9) 10.5 (6.3) 0.137 
Hospital admission past 12 months, n (%)   0.227 
0 80 (61.5%) 51 (71.8%)  
1 19 (14.6%) 13 (18.3%)  
2 10 (7.7%) 3 (4.2%)  
3+ 17 (13.1%) 4 (5.6%)  
Data not available (n=4)    
Unscheduled attendance with asthma (GP or 
ER) past 12 months 
2 (0,6) 3 (1,5) 0.791 
Ever admitted to an Intensive Care Unit, n (%) 14 (10.8%) 12 (16.9%) 0.249 
Data not available (n=4)    
Ever invasive ventilation, n (%) 8 (6.2%) 6 (8.5%) 0.600 
Data not available (n=14)    
Eczema, n (%) 31 (23.8%) 4 (5.6%) <0.001 
Data not available (n=13)    
Nasal polyps, n (%) 30 (23.1%) 24 (33.8%) 0.197 
Data not available (n=16)    
FEV1 (%) 75.5 (19.7) 68.6 (19.0) 0.020 
FVC (%) 90.9 (17.0) 86.5 (21.0) 0.118 
FEV1/FVC (%) 69.2 (12.3) 64.6 (11.6) 0.013 
IgE (kU/L) 282 (93,754) 147 (72,285) 0.012 
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Figure 2. FeNO suppression curves (shown as median values, IQR) for subjects with initial 
FeNO≥45ppb and a positive suppression test (figure 2a, n=130) and a negative suppression test 
(figure 2b, n=71). Insert figures are median FeNO (IQR) for Day 0, 4 and 7. 
Figure 2a 
 
 
Figure 2b 
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Table 2. Baseline patient characteristics of the subjects who proceeded to 1 month monitoring with high dose ICS/LABA (salmeterol 50µg/fluticasone 
500µg Diskus one inhalation twice per day) - FeNO ≥45ppb and positive suppression test, n=89), FeNO ≥45ppb and negative suppression test, n=41 
and FeNO<45ppb (single centre low FeNO group, n=40) had identical one month monitored treatment. Data are shown as median (IQR), mean (SD) or 
n (%) as appropriate. 
 
 
 
 
FeNO Low 
 (n=40) 
FeNO High 
 
FeNO Low versus 
Positive Suppression  
 
Positive FeNO 
suppression test (n=89) 
Negative FeNO 
suppression test (n=41) 
   
FeNO Low versus        
Negative Suppression 
Female, n (%) 30 (75.0%) 58 (65.2%) 18 (43.9%) 0.267 0.004 
Age (years) 46.5 (12.6) 39.1 (15.3) 47.4 (15.1) 0.009 0.769 
Smoking; n (%)    0.313 0.403 
Never smoked 26 (65.0%) 69 (77.5%) 31 (75.6%)   
Ex-smoker 13 (32.5%) 18 (20.2%) 10 (24.4%)   
Current smoker   1 (2.5%) 2 (2.2%) 0 (0.0%)   
Atopic, n (%)a 20 (50.0%) 59 (66.3%) 22 (53.7%) 0.066 0.742 
ACQ-5 2.6 (1.4) 2.8 (1.4) 2.7 (1.4) 0.306 0.699 
FeNO (ppb) 28 (14,36) 85 (65,122) 83 (59,114) <0.001 <0.001 
Blood eosinophils (x109/L) 0.24 (0.10,0.50) 0.44 (0.21,0.80) 0.36 (0.22,0.64) 0.005 0.146 
Inhaled steroid (BDP equivalent  µg)b 1642 (400) 1659 (662) 1732 (748) 0.883 0.514 
On maintenance prednisolone, n (%) 23 (57.5%) 41 (46.1%) 22 (53.7%) 0.230 0.728 
Prednisolone dose (mg) 10.6 (5.5) 11.6 (6.2) 11.2 (7.8) 0.513 0.750 
Hospital admission past 12 months, n 
(%) 
   
0.076 0.743 
0 25 (62.5%) 59 (66.3%) 30 (73.2%)   
1 12 (30.0%) 12 (13.5%) 8 (19.5%)   
2 1 (2.5%) 7 (7.9%) 1 (2.4%)   
3+ 2 (5.0%) 11 (12.4%) 2 (4.9%)   
Unscheduled attendance with asthma 
(GP or ER) past 12 months 
 
4 (2,10) 2 (0,7) 4 (1,6) 0.074 0.230 
Ever admitted to an Intensive Care 
Unit; n (%) 
3 (7.5%) 
9 (10.1%) 4 (9.8%) 0.637 0.718 
Ever invasive ventilation, n (%) 2 (5.0%) 6 (6.7%) 1 (2.4%) 0.650 0.556 
Data not available (n=6) 0 (0.0%) 5 (5.6%) 1 (2.4%)   
Eczema; n (%) 6 (15.0%) 23 (25.8%) 3 (7.3%) 0.136 0.271 
Data not available (n=4)      
Nasal polyps; n (%) 12 (30.0%) 19 (21.3%) 14 (34.1%) 0.416 0.689 
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a= atopy defined with immunology test; skin prick or RAST positive to inhaled perennial allergen (cat, dog, house dust mite, mixed grasses) b = 
baseline dose of inhaled steroid as prescribed are equivalent dose of beclomethasone dipropionate (BDP)  
Data not available (n=7)      
FEV1 (%) 75.6 (19.9) 79.2 (18.5) 68.9 (17.6) 0.341 0.126 
FVC (%) 90.0 (18.1) 93.9 (16.3) 83.5 (21.1) 0.246 0.155 
FEV1/FVC (%) 67.3 (11.6) 69.7 (10.5) 66.7 (11.0) 0.268 0.811 
IgE (kU/L) 108 (48,303) 332 (99,750) 194 (93,381) 0.021 0.079 
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Figure 3. Blood eosinophils on Day 0 and Day 7 of the FeNO Suppression test in subjects with 
positive (figure 3a, n=83) and negative (figure 3b, n=37) suppression tests and in subjects not on 
maintenance prednisolone with positive (figure 3c, n=49) and negative suppression tests (figure 3d, 
n=15). Data is shown as median (IQR). 
 
 
 
Post one month monitoring after FeNO suppression test 
Of the subjects who successfully performed suppression testing, 130 subjects agreed to proceed to 
further monitoring for one month to assist with use of their inhaled treatment 89 (68%) with a 
positive test and 41 (58%) with a negative test (table 2). All of these subjects could use the Diskus 
device proficiently based on monitoring during the suppression test. Of these, 1 patient with a 
negative suppression test required a rescue course of steroids during the monitoring month and 5 
subjects did not complete monitoring. After performing 1 month monitoring, 54 of 85 subjects 
(64%) with a positive suppression test and 27 of 39 subjects (69%) with a negative suppression test 
had ≥70% adherence with salmeterol 50µg/fluticasone 500µg Diskus (mean adherence 81±12% 
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positive test versus 84±9% negative test). For subjects who failed to achieve ≥70% adherence 
during the 1 month monitoring period, both critical inhaler technique error and missed doses were 
common problems with mean adherence 45±18%. 
 
There was a strong relationship between FeNO at Day 7 of the FeNOsuppT and FeNO level after 
one month monitored treatment with good adherence which was also the case for subjects on 
maintenance prednisolone (figure 4). There was also a significant reduction in blood eosinophil 
counts in subjects with a positive suppression test and monitored good adherence over one month 
who were not taking prednisolone (median difference -0.25 (95% CI -0.37, -0.03, p<0.001), figure 
5c), which was not seen in those with a negative suppression test (median difference 0.11 (95% CI -
0.13, 0.19, p=0.88), figure 5d). A similar trend was observed when subjects on prednisolone were 
included (median difference -0.06 (95% CI -0.17, 0.02, p=0.054, figure 5a) however this just failed 
to reach statistical significance because as discussed above subjects on prednisolone had lower 
baseline blood eosinophil counts (figure 5); again, there was no difference in subjects with a 
negative suppression test (median difference -0.03. 95% CI -0.13, 0.08, p=0.71, figure 5b). The 
correlation between the day-7 biomarkers after FeNOSuppT and post one month monitoring values 
is shown in Figure 6 (FeNO, r=0.69; p<0·001, blood eosinophils r=0.60; p<0·001) with post one 
month monitoring FeNO generally lower than day-7 FeNO value.  
 
Predictive value of FeNO Suppression test 
We also examined the predictive value of a positive 7-day suppression test for FeNO level in 
subjects with good adherence after one month monitoring, using Receiver Operating Characteristic 
(ROC) analysis (Figure e7, online supplement). The area under the curve was 0·81 (95% CI, 0·72 – 
0·91) and the optimal cut-point for specificity and sensitivity was FeNO 35ppb (in severe asthma, 
FeNO<35ppb has been shown to be associated with significantly less airway reactivity, airflow 
limitation and hyperinflation and  significantly reduced emergency room and intensive care unit 
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admissions15). The sensitivity of a positive FeNOsuppT for post monitoring FeNO≤35ppb when 
adherent with treatment was 89% (95% CI, 76–96%) and specificity 61% (95% CI, 44-77%). In 
terms of predictive value, 40 of 54 positive tests had a post one month monitoring FeNO≤35ppb 
and 22 of 27 negative tests had a FeNO>35ppb giving a positive predictive value for a 
FeNO≤35ppb of 74% [95% CI, 65–81%] and a negative predictive value of 82% [95% CI, 65–
91%]. For the 14 of 54 subjects with FeNO>35ppb after 1 month monitoring, there was still 
significant suppression (baseline FeNO 97ppb [IQR, 81 - 190], Day 7 40 ppb [IQR, 32 - 69], 
Day 30 57ppb [IQR 41 - 68], p<0.001). 
 
FeNO low group 
In the low FeNO group (<45ppb), who proceeded to monitoring for one month (n=40, Table 2), 
again, despite being able to use the Diskus efficiently based on the initial dose taken in clinic and 
being informed and aware that they were being monitored, only 18 of 40 subjects (45%) achieved 
adherence ≥70% over the one month monitoring period (mean adherence 82±8%). For FeNO low 
subjects who failed to achieve ≥70% adherence during the 1 month monitoring period, both critical 
inhaler technique error and missed doses were again common with mean adherence 35±21%. For 
those subjects who were adherent over the 1 month period (n=18), there was a small change in 
FeNO (baseline median FeNO 32ppb, IQR 21, 41, post monitoring median FeNO 22.5ppb, IQR 16, 
35, p=0.045). There was no significant difference in blood eosinophil count (baseline median 0.26, 
IQR 0.17 – 0.52 versus post month median 0.27, IQR 0.10, 0.48, p=0.776) irrespective of being 
prescribed maintenance prednisolone. 
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Figure 4. Relationship between FeNO after 7-day suppression testing and FeNO after one month 
monitoring for subjects with good adherence (a) positive suppression test (n=54) and (b) negative 
suppression test (n=27). The same pattern was seen in subjects on prednisolone with good 
adherence (c) positive suppression test (n=28) and (d) negative suppression test (n=15). Insert 
figures are median FeNO (IQR). 
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Figure 5. Blood eosinophil counts at baseline and after one month monitoring for all subjects with 
good adherence and (a) positive suppression test (n=49) and (b) negative suppression test (n=20) 
and for subjects, not on prednisolone and a positive suppression test (figure 5c, n=24) and a 
negative suppression test (figure 5d, n=10). Insert figures are median blood eosinophil count (IQR).  
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Figure 6. Correlation between Day 7 biomarkers after suppression testing with post one month 
monitoring values for subjects with good adherence with high dose ICS/LABA ((≥70% adherence 
with salmeterol 50µg/fluticasone 500µg Diskus twice per day). Correlation coefficient was 
calculated using the Spearman’s rank method (FeNO, r=0.69; p<0·001 and blood eosinophils 
r=0.60; p<0·001,  = positive suppression test  = negative suppression test). 
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Lung function and asthma symptom scores 
Lung function data and ACQ-5 scores at baseline and post one month monitoring in all subjects 
with good adherence are shown in Table 3. There was a significant improvement in FEV1 in those 
with a positive suppression test (mean difference 242 ml, 95% CI 90, 395 ml, table 3) which was 
not seen in subjects with a negative suppression test (mean difference 122 ml, 95% CI -143, 389 ml, 
table 3). There was a significant improvement in ACQ-5 in both suppressor and non-suppressor 
groups, which was numerically greater in subjects with a positive suppression test (mean 
difference -1.2, 95% CI -0.9, -1.5) compared to those with a negative suppression test (mean 
difference -0.9, 95% CI -0.4, -1.3) and there was a significant correlation between % fall in FeNO 
and % improvement in ACQ-5 in all FeNO high subjects (r=0.39, p<0.001). For the 14 of 54 
subjects with a positive FeNOSuppT and FeNO>35ppb after 1 month monitoring, there were 
significant improvements in FEV1% (81.9±20.1% to 91.9±19.2%, p=0.05) and ACQ5 (2.49±1.5 to 
1.65±0.99, p<0.05). There was no change in ACQ-5 with monitored treatment with good adherence 
in subjects with initial FeNO<45ppb (table 3) and no improvement in lung function (mean 
difference -114 ml, 95% CI -267, 37 ml, table 3). 
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Table 3. Lung function data and ACQ-5 scores and values at baseline and post one month 
monitoring in subjects with good adherence. 
 
 FeNO≥45ppb - Positive Suppression 
Test (n=54) 
FeNO≥45ppb - Negative Suppression 
Test (n=27) 
FeNO<45ppb (n=20) 
 Baseline 
(Day 0) 
Post 
monitoring 
period 
P value Baseline  Post 
monitoring 
period 
P 
value 
Baseline  Post 
monitoring 
period 
P 
value 
FEV1(L) 2.65±0.87 2.89±0.82 0.003 2.28±0.67 2.40±0.78 0.35 2.29±0.42 2.18±0.42 0.13 
FEV1 % 
predicted 
80.1±16.4 88.2±16.4 0.001 70.1±16.0 74.1±20.9 0.30 74.5.0±12.0 71.0±14.5 0.15 
FVC (L) 
 
3.69±0.97 3.88±0.98 <0.001 3.50±0.84 3.45±0.91 0.71 3.42±0.67 3.35±0.61 0.44 
FVC % 
predicted 
93.3±13.2 98.1±14.0 <0.001 86.1±15.9 85.4±19.8 0.83 89.3±11.0 87.6±10.6 0.50 
FEV1/FVC 
ratio 
71.2±8.8 74.7±9.1 0.049 64.6±8.9 69.2±12.5 0.12 66.9±10.0 65.2±9.9 0.08 
ACQ-5 2.76±1.25 1.55±1.21 <0.001 2.81±1.61 1.96±1.43 <0.001 1.96±1.35 1.79±1.32 0.32 
 
 
 
Discussion  
This study demonstrates in subjects with difficult-to-control severe asthma and FeNO ≥45ppb, 65% 
had a positive FeNOsuppT and with effective adherence to LABA/ICS during a one month 
monitored period, there were significant improvements in both symptoms and lung function and 
FeNO was maintained at target levels associated with reduced exacerbation, emergency room 
attendances and ICU admissions15,16. In contrast, among those with a negative suppression test, 
there was a lesser reduction in FeNO despite taking high dose ICS/LABA efficiently, with no 
improvement in lung function and less improvement in symptoms. 
 
The original description of the FeNOSuppT previously used physician directly-observed treatment 
(DOT) over 7 days and defined a positive FeNOsuppT for non-adherence on poor prescription 
filling. The remote monitoring acoustic technology in this study effectively delivers DOT by time-
stamping inhaler activation and analysing inhalation technique which also identifies “non-
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intentional” non-adherence, where critical inhaler errors prevent effective treatment which is known 
to be a common problem17. Given these patients were prescribed high dose ICS/LABA at the time 
of FeNOsuppT, we believe the suppression of FeNO with effectively administered ICS/LABA 
treatment reflects prior inefficient ICS treatment due to both intentional and non-intentional non-
adherence.  
 
In subjects with a positive FeNOsuppT, there was also a significant fall in blood eosinophil counts 
consistent with both biomarkers being ICS responsive when adherent with monitored treatment. 
Composite biomarker profiling using FeNO and blood eosinophil count allows better prognostic 
risk stratification with highest risk seen when both Type-2 biomarkers are high and vice versa18,19, 
suggesting that for subjects with a positive FeNOsuppT and resultant biomarker low profile with 
good adherence, there should be a parallel risk reduction for exacerbations. The longer term clinical 
and adherence outcomes for subjects characterised using FeNOsuppT in a severe asthma population 
are currently being studied (ClinicalTrials.Gov NCT02307669), but it is worth commenting that a 
small number of subjects, despite a good response to monitored treatment in terms of FeNO, ACQ-
5 and lung function improvement, have a persistent elevated peripheral blood eosinophil count. This 
suggests that the biological driver of blood eosinophils in these subjects may not be as ICS 
responsive as FeNO, and we are also currently exploring the clinical significance of this 
“dissociated” biomarker profile in terms of exacerbation risk and clinical outcome 
(ClinicalTrials.Gov NCT02717689). However, our data suggest that the biomarker profile (FeNO 
and blood eosinophil count) after 1 week of FeNOsuppT is closely related to the profile when 
taking optimised ICS/LABA treatment, thus facilitating identification of subjects where adherence 
intervention to optimise inhaled treatment may be of most value prior to considering treatment 
escalation but also potentially identifying those subjects who are likely remain biomarker high 
despite optimised ICS/LABA treatment and suitable for novel type 2 biologic therapies. Maximal 
FeNO suppression has also been shown after 7 days high dose ICS treatment in mild asthma7,20,21 
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and our data suggests that similar maximal suppression is seen in subjects with more severe asthma 
given the strong correlation between day 7 FeNO post FeNOSuppT and post monitoring FeNO. In 
those subjects despite having with a positive test and FeNO >35ppb after monitoring, significant 
falls in both FeNO was seen compared to baseline with improvements in lung function and 
symptom scores consistent with prior ICS non-adherence and suggesting a period of optimised 
inhaled treatment with clinical monitoring prior to treatment escalation is appropriate. 
 
Poor-adherence is common in subjects with severe asthma1.2,3. The availability of novel biologic 
therapies targeting type-2 cytokines makes identification of sub-optimal adherence to ICS important 
so that these issues can be explored prior to treatment escalation. An attractive proposition is to 
move away from using imperfect surrogate measures of adherence (e.g. patient self-report, 
physician impression, prescription records) to using an ICS responsive biomarker (FeNO) as part of 
a clinical phenotyping strategy and precision medicine delivery. The FeNO-low group 
(FeNO<45ppb) demonstrate a small reduction in FeNO with monitored optimised treatment with 
ICS/LABA with a FeNO in a similar range to those subjects with a positive suppression test and 
optimised treatment. There was no change in peripheral blood eosinophil count, ACQ-5 or lung 
function, which may reflect the fact that this low FeNO group are more adherent to background ICS 
treatment and the potential for further clinical improvement with optimised ICS/LABA in this 
FeNO-low group is less.  
 
A strength of this data is that it occurred in a “real world” setting, by-passing the challenging aspect 
of engaging a non-adherent difficult-to-control asthma population in a clinical trial22. As well as 
providing insight into ICS therapeutic response in a short period of time, this approach identifies 
subjects who can use a particular inhaler efficiently and wish to engage with a monitoring strategy 
to assist them with their inhaler use. However, it is worth emphasising that 70 of 169 subjects 
[41%] failed to take ≥70% or complete 1 month monitoring of inhaled treatment despite being 
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proficient in inhaler use and keen for support, suggesting there are barriers to even short-term use of 
technological support to assist with inhaled treatment adherence. If these barriers could be identified 
and addressed, there could be substantial gains with optimised use of high dose ICS/LABA 
treatment in this poorly controlled, high-risk asthma population, however defining the best 
intervention to change non-adherent behaviour is outwith the scope of this study. Only 16 patients 
were unable or forgot to perform daily FeNO during the 7-day home assessment suggesting that this 
is not a major barrier to home delivery of domiciliary FeNOSuppT, however inadequate use of the 
monitored ICS was more common. 
 
Formal cost-effectiveness analysis of ‘biomarker-based’ assessments with adherence monitoring is 
also required, however this seems likely by identifying subjects who may achieve adequate asthma 
control without the need for treatment escalation to expensive biologic agents. Subjects with a 
positive FeNOSuppT were younger with more eczema and higher IgE suggesting greater ICS 
responsiveness in this group though hospital admissions were equally prevalent in the high FeNO 
group with positive and negative suppression tests. In the National Heart, Lung, and Blood Institute 
Severe Asthma Research Program, a high FeNO (>35ppb) was associated with greater emergency 
room visits and hospital and ICU admissions and again in a younger, more atopic patient cohort15. 
If adherence could be satisfactorily addressed in this ICS responsive FeNO high difficult-to-control 
asthma population, there could potentially be a substantial impact on hospital admission rates. 
 
In summary, we have demonstrated that and FeNOsuppT can be delivered using remote monitoring 
technology in routine clinical care in specialist severe asthma services in the UK. Short-term 
profiling of the FeNO response to ICS exposure in subjects with difficult-to-control severe asthma 
is a helpful part of clinical phenotyping to identify those who are likely to respond better to high 
dose ICS/LABA therapy when used regularly and those who, despite good adherence with inhaled 
treatment, are likely to require additional treatment. In addition, aligning monitoring of ICS 
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treatment with FeNO response may be of value in identifying ICS responsive subjects prior to 
recruitment to clinical trials investigating interventions which are “add-on” treatments to standard 
care (ICS/LABA) and also to studies investigating “true” ICS resistant disease. Future studies are 
required to identify the optimal intervention to maintain ongoing adherence in a difficult-to-control 
severe asthma population, but understanding the potential therapeutic benefit in an individual 
patient is a useful part of routine care. 
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Supplementary Methods 
Acoustic Monitoring Technology 
The INCA™ device is attached to the Accuhaler and a microphone is activated when the device is 
opened and stops when the inhaler device is closed (Figure e1). If the inhaler device is left open, the 
recoding automatically shuts off after 90 seconds. 
 
The INCA™ Analysis software processes the sound files generated by the INCA™ device to assess 
if the inhaler has been taken properly (Figure e2). Most of the inhalations during the service 
evaluation were deemed satisfactory by the software and any “technique errors” identified by the 
software, were subsequently manually over-read by the clinical team. 
 
Feedback from the 7 day Flixotide Accuhaler technique and usage (Figure e3) during the FeNO 
suppression testing was also examined to ensure that patients could use the Accuhaler device 
efficiently. If this was the case and patients wished to continue to use the technology to assist with 
their inhaled treatment, they were then provided with a salmeterol 50µg/fluticasone 500µg 
Accuhaler with INCA™ device to be taken once in the morning and once in the evening (standard 
high dose ICS/LABA therapy) and again instructed in inhaler use. On return to the clinic, the data 
was uploaded and an easily interpretable readout was produced for the clinician to provide further 
feedback to the patient (figure e4). 
 
Positive FeNO suppression test  
A positive FeNO suppression test was defined as previously with a Lg10FeNO greater than or 
equal to 0.24 where Lg10FeNO was calculated as {mean (Lg10 FeNO Day0, Lg10FeNODay 1)} -
{mean(Lg10 FeNO Day 4, Lg10 FeNO Day 5)}. In effect, a 42% fall in FENO between the 
Day 0/Day 1 and the Day 4/Day 5 mean values equates with a positive suppression test. 
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Figure e1. INCA™ device which is attached to Accuhaler inhaler. 
   
     
 
 
Figure e2. Example of sound file and semi-automated analysis
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Figure e3. Data from the Vitalograph server following upload of one week FeNO suppression data 
and INCA™. The Vitalograph server shows activation and usage of both FeNO machine and 
INCA™ device (figure e3A) and depicts the FeNO data as precentage change from baseline as 
originally described (y1-aixs figure A). The INCA™ device time and date stamps the number of 
inhaler uses (y2-axis – Figure A) and this is shown alongside technique analysis (figure e3B). 
Possible technique errors which can be indentified and reported are shown in Graphic 3.  
 
Figure e3A  
 
                     
Figure e3B 
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Figure e4.  Data from the Vitalograph server following upload of one month salmeterol 
50µg/fluticasone 500µg Accuhaler bd INCA™ soundfiles. The Vitalograph server shows usage of 
the INCA™ device which time and date stamps the number of inhaler uses (A) and technique 
analysis (B). Possible technique errors which can be indentified and reported are shown in the 
graphic in figure e3. 
 
Figure e4A 
 
 
Figure e4B 
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Supplementary Results 
Table e1. Baseline patient characteristics of the 290 patients attending severe asthma clinics due to 
poor asthma control. Patients with FeNO ≥45ppb (multicentre high FeNO group, n=250) had FeNO 
suppression testing and patients with FeNO<45 ppb (single centre low FeNO group, n=40). Data 
are shown as median (IQR), mean (SD) or n (%) as appropriate 
 
 
a = atopy defined with immunology test; skin prick or RAST positive to inhaled perennial allergen 
(cat, dog, house dust mite, mixed grasses) b = baseline dose of inhaled steroid as prescribed are 
equivalent dose of beclomethasone dipropionate (BDP)  
 FeNo High (n=250) FeNO Low (n=40) P value 
Female, n (%) 147 (58.8%) 30 (75.0%) 0.051 
Age, (years)  43.6 (15.9) 46.5 (12.6) 0.279 
Smoking, n (%)   0.151 
Never smoked 194 (77.6%) 26 (65.0%)  
Ex-smoker 49 (19.6%) 13 (32.5%)  
Current smoker   3 (1.2%) 1 (2.5%)  
Data not available (n=4)    
Atopic, n (%)a 146 (58.4%) 20 (50.0%) 0.230 
Data not available 7 (2.8%) 0 (0.0%)  
ACQ-5  2.8 (1.4) 2.6 (1.4) 0.314 
FeNO (ppb) 81 (58,114) 28 (14,36) <0.001 
Eosinophils (cells x 109/L) 0.41 (0.23,0.69) 0.24 (0.10,0.50) 0.006 
Inhaled steroid (BDP equivalent  µg)b  1701 (683) 1642 (400) 0.606 
On maintenance prednisolone; n (%) 130 (52.0%) 23 (57.5%) 0.534 
Data not available (n=1)    
Prednisolone dose (mg); Mean ± SD 11.7 (7.1) 10.6 (5.5) 0.470 
Hospital admission past 12 months; n (%)   0.095 
0 167 (66.8%) 25 (62.5%)  
1 37 (14.8%) 12 (30.0%)  
2 14 (5.6%) 1 (2.5%)  
3+ 26 (10.4%) 2 (5.0%)  
Data not available (n=6)    
Unscheduled attendance with asthma (GP or 
ER) past 12 months; median (IQR) 3 (0,5) 4 (2,10) 0.043 
Ever admitted to an Intensive Care Unit; n (%) 30 (12.0%) 3 (7.5%) 0.380 
Data not available (n=6)    
Ever invasive ventilation; n (%) 15 (6.0%) 2 (5.0%) 0.728 
Data not available (n=17)    
Eczema; n (%) 37 (14.8%) 6 (15.0%) 0.811 
Data not available (n=26)    
Nasal polyps; n (%) 65 (26.0%) 12 (30.0%) 0.940 
Data not available (n=29)    
FEV1 (%); Mean ± SD 72.9 (20.2) 75.6 (19.9) 0.464 
FVC (%); Mean ± SD 89.1 (19.1) 90.0 (18.1) 0.789 
FEV1/FVC (%); Mean ± SD 67.5 (12.5) 67.3 (11.6) 0.917 
IgE (kU/L); Median (IQR) 182 (74,616) 108 (48,303) 0.163 
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Figure e5. FeNO suppression curves (shown as % of baseline) for subjects with initial FeNO≥45 
ppb and a positive suppression test (figure e5a, n=130) and a negative suppression test (figure e5b, 
n=71). Insert figures are median % of baseline FeNO (IQR). 
 
Figure e5a 
 
 
Figure e5b 
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Figure e6. FeNO suppression curves (shown as median values, IQR) for subjects on maintenance 
prednisolone with initial FeNO≥45 ppb and a positive suppression test (figure e6a, n=61) and a 
negative suppression test (figure e6b, n=45). Insert figures are median FeNO (IQR) for Day 0, 4 and 
7). 
Figure e6a 
 
Figure e6b 
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Receiver Operator Characteristic analysis 
We used ROC analysis to examine the predictive value of a positive suppression test for the FeNO 
level at the end of the one month monitoring period in patients with good adherence with high dose 
ICS/LABA (≥70% salmeterol 50µg/fluticasone 500µg Accuhaler one inhalation twice per day) 
(Figure e7). The area under the curve was 0·81 (95% CI, 0·72 – 0·91) and the best cut point for 
specificity and sensitivity using the formula d= √[(1 – sn)2 + (1 – sp)2] was FeNO 35 ppb. The 
sensitivity of a positive FeNO suppression test for post monitoring FeNO ≤35ppb when adherent 
with treatment was 89% (95% CI, 76 –  96%) and specificity 61% (95% CI, 44 - 77%). In terms of 
predictive value, 40 of 54 positive tests had a post one month monitoring FeNO ≤35ppb and 22 of 
27 negative tests had a FeNO >35ppb giving a positive predictive value for a FeNO ≤35ppb of 74% 
[95% CI, 65 – 81%] and a negative predictive value of 82% [95% CI, 65 – 91%]. 
 
  
40 
 
Figure e7 ROC analysis examining the predictive value of a positive suppression test for one month 
post monitoring FeNO in those patients with good adherence with high dose ICS/LABA ((≥70% 
salmeterol 50µg/fluticasone 500µg Accuhaler one inhalation twice per day).  
 
 
 
 
 
 
 
 
